News Room Archive
13 December, 2006 - Bayer donates antibiotics with a wholesale value of more than US$ 25 million to MAP International for Africa and Latin America
The aid organization will distribute the critically needed antibiotic to clinics and hospitals in Africa and Latin America that are fighting on the front lines in the battle against diseases of poverty where there is little or no access to essential medicines.
11 December 2006 - Data From Phase III Comparative Study Show Campath(R) Superior to Chlorambucil as a First-line Therapy in
B-CLL
Study met primary endpoint of progression free survival with Campath
27 November 2006 - Wenning: Schering acquisition provides additional boost to Bayer
Fall Financial News Conference 2006 of Bayer AG
09 November 2006 - Bayer Outlines New Global R&D Structures; U.S. Pharma Sites and Future Headquarters
Bayer HealthCare announced today a structural realignment of its global pharmaceutical research and development organization.
08 November 2006 - Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications
Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications
31 October 2006 - Bayer’s Perspective on Innovation 2006 Wenning: “Research is the key to success”
• Three new patent applications every working day help safeguard Bayer’s future
• Technology of the future: plant-made pharmaceuticals
• Group-wide innovation initiative “Triple-i” successfully launched
31 October 2006 - Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin’s Lymphoma
– Twenty-five study centers currently open across the U.S. –
26 October 2006 - What Do Doctors Know and Women Don't?
The IUC is a Preferred Contraceptive of Female Ob/Gyns in the U.S.
23 October 2006 - FDA Approves Betaseron for Use After the First Event Suggestive of Multiple Sclerosis
Early treatment with Betaseron significantly delayed the time to a second clinical event
18 October 2006 - Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Regeneron Retains U.S. Commercialization Rights, Receives $75 Million Upfront, and Eligible for up to $245 Million of Milestone Payments
05 October 2006 - FDA Approves new Indication for YAZ® to Treat Emotional and Physical Symptoms of Premenstrual Dysphoric Disorder (PMDD)
YAZ is the First and Only Birth Control Pill With Proven Efficacy for PMDD
09 September 2006 - Schering acquisition: Bayer reaches squeeze-out threshold
Bayer has purchased further shares of Schering on the stock market and on Friday, September 8, 2006 increased its holding to more than 95 percent, the proportion required to effect a “squeeze-out” of minority stockholders.
31 July 2006 - Berlex Voluntarily Recalls Ultravist® Injection 370 mgI/mL
Berlex, Inc., a US affiliate of Schering AG, Germany, is voluntarily recalling all lots of its X-ray contrast agent Ultravist® Injection 370 mgI/mL (iopromide injection), as part of a worldwide recall, due to the potential that particulate matter in conjunction with crystallization may be present in the product.
See More
23 July 2006 - Nexavar® Approved by European Commission for the Treatment of Advanced Kidney Cancer
Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization to Nexavar® (sorafenib) tablets
See More
21 July 2006 - Berlex Issues Nationwide Recall of a Single Lot of ULTRAVIST® Injection 370 mgI/mL, 125 mL in the U.S.
Berlex, Inc. has initiated a nationwide recall of a single lot (No. 41500A) of its intravenous X-ray contrast agent, Ultravist® Injection 370 mgI/mL, 125 mL, (iopromide injection) NDC 50419-346-12, EXP 01/2007, due to the presence of particulate matter in conjunction with crystallization.
See More
18 July 2006 - Bayer HealthCare and BioRx Introduce Educational Children’s Book About Hemophilia The Great Inhibinator is an inspiring story that will be a valuable teaching tool for parents and healthcare providers dealing with inhibitors
See More
17 July 2006 - Bayer HealthCare Introduces Free Product Trial Program For Kogenate® FS with BIO-SET
Individuals living with hemophilia A in the United States can now experience the safety, simplicity, and convenience of treatment with the first needleless reconstitution device for rFVIII treatment
See More
11 July 2006 - New Autoinjection Device Designed to Work with Betaseron now Available for Patients with Multiple Sclerosis
Betaject®3 Offers Convenient Delivery Option
See More
10 July 2006 - New Study Reveals Barriers to Reproductive Health Care in US Latino Community
Communication Among Couples and Improved Education Needed
See More
26 June 2006 - Washington University and Berlex Collaborate on Research Fellowship
Today Berlex, Inc., announced a collaboration with the Mallinckrodt Institute of Radiology at the Washington University School of Medicine in St. Louis that includes the creation of a post-doctoral research fellowship in the field of diagnostic imaging contrast agents.
See More
21 June 2006 - Company’s biggest-ever transaction successful!
Bayer and Schering optimistic about their common future
See More
14 June 2006 - Pfizer Signs Agreement with Bayer to License Compounds for Potential Treatment of Obesity, Diabetes and Related Disorders
Pfizer Inc. and Bayer Pharmaceuticals Corporation, the U.S. subsidiary of Bayer HealthCare, announced today that they have entered into an agreement granting Pfizer exclusive worldwide rights to Bayer's DGAT-1 inhibitors, an innovative class of compounds that modify lipid metabolism.
See More
13 June 2006 - Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
The updated analysis confirmed that overall survival was longer for Nexavar than for placebo patients.
See More
07 June 2006 - New Survey Suggests Couples May Need Help Keeping Their Romance Alive This Summer
Today's demanding lifestyles make it a challenge for couples to feel free to be romantic – especially for parents who have even less time together now that kids are out of school for the summer.
See More
05 June 2006 - Updated Overall Survival Analysis Presented on Nexavar Phase III Trial
The updated analysis confirmed that overall survival was longer for Nexavar than for placebo patients.
See More
03 June 2006 - Genzyme and Berlex Oncology Announce Interim Results of Campath in First-Line Study of Chronic Lymphocytic Leukemia at ASCO
Initial data from a Phase III comparative study suggest efficacy and safety with Campath®, even in poor-prognosis patients
See More
25 May 2006 - Bayer HealthCare, The National Hemophilia Foundation, and Andretti Green Racing Announce Racing for Hemophilia Primary Donor for the 2006 Indianapolis 500
Successful program raised money and awareness for hemophilia A
See More
24 May 2006 - Promising Early Clinical Trials for Bayer’s Longer Acting Kogenate® Product
Data from two early-stage clinical trials presented today at the World Federation of Hemophilia (WFH) conference offer promising results and support further development for a new experimental factor VIII replacement product, BAY 79-4980.
See More
23 May 2006 - Bayer Grant Promotes Groundbreaking Hemophilia Research and Education
Bayer Hemophilia Awards Program continues to be a critical source of funding for hemophilia research and education
See More
22 May 2006 - New study data confirm excellent speed of eradication by Avelox® (moxifloxacin HCl)
Complete eradication of pathogens in acute bacterial sinusitis after only three days of treatment
See More
3 May 2006 - Enrollment Completed in Phase III Studies of Nexavar for Patients with Metastatic Melanoma and Liver Cancer
Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. today announced the completion of patient enrollment in two randomized, double-blind Phase III clinical trials; one administering Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced metastatic melanoma and another administering Nexavar as a single agent in patients with advanced hepatocellular carcinoma (HCC), or liver cancer.
See More
28 April 2006 - Nexavar® Receives Positive Opinion from European Committee for Medicinal Products
for Human Use
Renal Cell Carcinoma Approval Received in Mexico
See More
27 April 2006 - Experts recommend Aspirin® for the treatment of migraine
The active ingredient acetylsalicylic acid (ASA) provides safe, reliable relief
See More
27 April 2006 - GIANT Study: Many more women affected by acute exacerbations of chronic bronchitis (AECBs) than widely believed
Largest ever antibiotic study sheds new light on AECBs and confirms effective antibiotic therapy with Avelox® can reduce the significant negative impact on patients’ quality of life
See More
27 April 2006 - Bayer achieves record earnings
Interim report for the first quarter of 2006
See More
26 April 2006 - FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Nexavar® (sorafenib) tablets has been granted orphan drug status for the treatment of hepatocellular carcinoma (HCC), or liver cancer, by the U.S. Food and Drug Administration (FDA).
See More
19 April 2006 - New YAZ® Oral Contraceptive Available in the United States
New YAZ® Oral Contraceptive Available in the United States
See More
18 April 2006 - European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Nexavar® (sorafenib) tablets has been granted orphan medicinal product status for the treatment of hepatocellular carcinoma (HCC), or liver cancer, by the European Commission.
See More
13 April 2006 - Bayer makes official takeover offer for Schering
Acceptance period for the offer of EUR 86 per share ends on May 31, 2006 / Wenning: Offer is a worthwhile one for Schering shareholders
See More
05 April 2006 - As first-line erectile dysfunction treatment for men, Levitra provides sexual satisfaction for couples
In this first study of its kind in men with erectile dysfunction who had not previously been treated with a phosphodiesterase type 5 (PDE5) inhibitor, 81% of men who took Levitra (vardenafil) reported improved erections (81% with Levitra vs 30% who took a placebo; p<0.0001).
See More
04 April 2006 - Sixteen-Year Follow-up Study Reinforces Betaseron® Long-Term Efficacy, Safety and Tolerability in Multiple Sclerosis
Efficacy in relapse rate reduction beyond five years shown for the first time
See More
30 March 2006 - Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer
First European Approval in New Class of Cancer Therapy
See More
17 March 2006 - FDA Approves Yaz, the First Oral Contraceptive to Offer Drospirenone in a 24-day, Active-Pill Regimen
Berlex, Inc., a U.S. affiliate of Schering AG, Germany (FSE: SCH; NYSE: SHR), announced today that the U.S. Food and Drug Administration (FDA) has approved YAZ® (3 mg drospirenone/20 mcg ethinyl estradiol), a new monophasic oral contraceptive (OC) and the first pill to combine 20 mcg of ethinyl estradiol with the innovative progestin drospirenone (drsp).
See More
24 February 2006 - East meets West when Jerry Hall addresses Asian conference as global ambassador for new erectile dysfunction campaign
Model, actress and icon, Jerry Hall appears alongside renowned sexual specialists at the ‘A Couple’s Solution’ press seminar to encourage men and women globally to Strike Up A Conversation and openly discuss erectile dysfunction with each other and with healthcare professionals.
See More
23 February 2006 -Berlex Files Application for Use of Betaseron in Patients with a First Clinical Episode
Berlex, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental biologics license application (sBLA) requesting an expanded label for its multiple sclerosis (MS) therapy, Betaseron® (interferon beta-1b).
See More
16 February 2006 - Bayer and Onyx Initiate Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar (sorafenib) tablets in Combination with Two Chemotherapeutic Agents
West Haven Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc. today announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial studying Nexavar® (sorafenib) tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC)
See More
08 February 2006 - IMPORTANT Trasylol Safety Information
This information is for all U.S. Healthcare Professionals!
See More
08 February 2006 - Bayer and Global Regulatory Authorities Evaluating Published Reports on Trasylol
Bayer will publish and mail letters to Health Care Professionals
See More
0 2 February 2006 - Image of Multiple Sclerosis Captured through Photographic Exhibit By Renowned Photographer
The Image of MS Chronicles Personal Stories from Men and Women with MS
See More
25 January 2006 - FDA clarifies status of YAZTM PMDD application
Schering AG, Germany (FSE: SCH, NYSE: SHR) announced today that its U.S. affiliate, Berlex, Inc., has received an approvable letter from the U.S. Food and Drug Administration (FDA) indicating that the premenstrual dysphoric disorder (PMDD) application for YAZ™ is approvable pending their review of recently submitted data and their satisfactory conclusion on its content.
See More
20 January 2006 -Berlex, Amerinet Extend and Enhance Agreement for Contrast Media Therapy Patch, Climara Pro®
Ultravist® Joins Magnevist® as part of Amerinet’s Portfolio of Contracted Contrast Agents
See More
05 January 2006 - Bayer HealthCare and Nuvelo Enter Into Collaboration Agreement for Global Development and Commercialization of Alfimeprase
Product Perfectly Complements Bayer´s Hematology and Cardiology Portfolio
See More
04 January 2006 - FDA Approves Osteoporosis Indication for Once-A-Week Hormone Therapy Patch, Climara Pro®
First and only once-a-week combination patch for osteoporosis
See More
03 January 2006 - Bayer HealthCare purchases Pritor business from GlaxoSmithKline
Strategic fit for Bayer´s pharma business.
See More
